Biotech company 10x Genomics filed two lawsuits against rival Illumina in Delaware federal court on Tuesday, accusing ...
Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...
Illumina is rated a BUY as it drives growth with AI, multiomics, and strategic acquisitions. Click here to read my earnings ...
The Broad Institute gene-sequencing lab used Roche equipment to read infants’ DNA genomes in less than four hours, cutting an ...
On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...
The company's multi-year strategy involves the rollout of new products and upgrades to existing ones that further strengthen its position.
8d
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina, Inc. (NASDAQ: ILMN) announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's ...
The Print on MSN
Doctors still treat heart disease with trial and error. This start-up wants to change that
India-specific database of Coronary Artery Diseases will help identify if a person has a risk factor of developing heart ...
12d
A Look at Illumina’s (ILMN) Valuation Following the Launch of BioInsight and Executive Team Updates
Illumina (ILMN) just launched BioInsight, a new business unit focused on combining sequencing, software, and AI for advanced biological insights. Executive changes and this expansion highlight the ...
US-based company is developing next-generation sequencers, using AI models in the Republic to speed up diagnostics and lower ...
Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights: San Diego Friday, October 17, 2025, 17:00 Hrs [IST] Illu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback